TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02088931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treg infusion
Description: At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease \<50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
Study: NCT00841191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
Study: NCT02815956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous tibial nerve stimulation
Study: NCT03333668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine dimesylate
Description: Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine Extended Release Oral Tablet
Description: Guanfacine Extended Release (0.05mg/kg) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release Oral Tablet
Description: Guanfacine Extended Release (0.05mg/kg) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Vitamin C (10mg) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Vitamin C (10mg) tablet
Study: NCT00976742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Study: NCT00841191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
Study: NCT01043640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
Study: NCT00841191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
Study: NCT01043640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Administered every 6 hours: If \< or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If \> 12 kg then 0.8 mg/kg/dose IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Description: Administered \> 24 hours after last dose of busulfan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: 2.5 mg/kg/dose intravenous (IV_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:~* If body weight is ≤ 40 kg dosing will be 3 times daily~* If body weight is \> 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC\>500 x 10\^6 neutrophils/L x 3 days and chimerism \>90%), whichever is later.
Study: NCT03983941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Total dose not to exceed 3 mg/kg of ropivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Total dose not to exceed 3 mg/kg of ropivacaine.
Study: NCT01243476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral use, daily during study treatment (104 weeks)
Study: NCT02888626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microlens Array
Description: Treatment with Cutera Microlens Array Device used with the enlighten™ 532nm /1064nm/670nm laser
Study: NCT01037712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir (ZELITREX)
Description: 2g, 8g/day, 4 a day 23 weeks maximum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03820115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder
Description: Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
Study: NCT00841191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
Study: NCT02043574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise
Description: Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stretching (control)
Description: Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
Study: NCT01480986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan combined with cisplatin, octreotide lar
Description: Phase 1 irinotecan 180mg/m\^2，ivgtt，90min，D1 Cisplatin 50 mg/m\^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
Study: NCT00608140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical mitral valvuloplasty with placement of annular ring (SMVR)
Description: Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical mitral valvuloplasty with placement of annular ring (SMVR)
Description: Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT)
Description: Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy (OMT)
Description: Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT)
Description: Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
Study: NCT02625038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUDAMED CIV-14-03-011940
Study: NCT00841191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H\&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
Study: NCT02574377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: myDC vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: pDC vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: combined myDC/pDC vaccination
Study: NCT03502889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPANK Block (Sensory Posterior Articular Nerves of the Knee)
Description: Injection of local anesthetic into the tissues on the posterior aspect of the knee to provide sensory blockade of the articular nerves of the knee.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hcl 0.5% Inj Vil 30Ml
Description: Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hcl 0.5% Inj Vil 30Ml
Description: Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pajunk sonoplex stim needle
Description: Echogenic needle used for ultrasound guided nerve blockade.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pajunk sonoplex stim needle
Description: Echogenic needle used for ultrasound guided nerve blockade.
Study: NCT01505933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Administer dexmedetomidine at 1mcg/kg over 10min followed by an infusion of dexmedetomidine at 1mcg/kg/hr and image the upper airway.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of dexmedetomidine 2mcg/kg followed by increase in the infusion rate to 3mcg/kg/hr. Upper airway images will be repeated 5mins after increasing infusion Image acquisitions will be repeated approximately 5 min after the increase in infusion rate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Administer propofol bolus at 2mg/kg,followed by an infusion of propofol at 100 mcg/kg/min. Upper airway images will be obtained 5 mins after the patient is stable on this infusion.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of 1mg/kg propofol and infusion increased to 240mcg/kg/min.~Image acquisitions will be repeated approximately 5 min after the increase in infusion rate.
Study: NCT00117312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
Study: NCT01167608

Intervention type: OTHER
Intervention: No Intervention. This is a cross-sectional survey study.
Description: No intervention.
Study: NCT01409889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Program
Study: NCT03944837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: Transient maternal oxygen administration during echocardiographic and MRI imaging
Study: NCT03338946

Intervention type: DEVICE
Intervention: CIED interrogation
Description: CareLink Express interrogation
Study: NCT01243931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCT-guided laser phototherapeutic keratectomy
Description: Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
Study: NCT00515125

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary Advice
Description: Dietary Advice sheet

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Supplements (Fortisip)
Description: These products are classified as non-medicinal, borderline substances, foods for special medical purposes.~A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 12 week period.
Study: NCT03832361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN853
Description: IMGN853 6 mg/kg intravenously every 3 weeks until disease progression
Study: NCT04131621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab/Ipilimumab
Description: Immune checkpoint inhibitor combination
Study: NCT03401749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate 2% Wipe
Description: Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraworx Bath Wipes
Description: Theraworx TM is a cosmetic product that is a non-rinse skin formulation that combines multiple ingredients, including Aloe Concentrate, Allantoin, Tego Betaine F 50, Tego Betaine L-7, Lauryl Glucoside, Abil 8852, Vitamin E, Natural Fragrances, Methyl paraben, Propyl paraben, EDTA, Antimicrobial Preservative, Colloidal Silver, and Beta Glucan, in preoperative disposable bath wipes. The main proposed antimicrobial mechanism of action involves the local reduction in skin pH to around 4.6.
Study: NCT03619915

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres
Study: NCT02815956

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02845492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Health Improvement Program (CHIP)
Description: The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
Study: NCT00838630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg tablets
Description: 1 x 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pletal® 100 mg tablets
Description: 1 x 100 mg
Study: NCT04377386

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1000 IU D vitamin
Description: Participants in the intervention group will receive 105 DV doses of 1000 IU. The supplementation will be given by the Farma de Colombia laboratory, known commercially as Farma D, whose presentation is in soft gelatin capsules. It is recommended to take one dose per day at the same time and participants should record the daily intake time of the supplement for 15 weeks on a calendar.
Study: NCT03876054

Intervention type: DEVICE
Intervention: Spinal cord stimulation (SCS)
Description: Subjects will be implanted with market-released Abbott SCS systems